Where to Buy Semaglutide Online: Compounded vs Branded, and What to Verify

The approved semaglutide products are manufactured under FDA-inspected conditions, come in a pre-filled pen at fixed doses, and are the products the STEP and SELECT trials were run on. Whether you pay a copay or the full cash price depends entirely on your plan's criteria. For many people with a qualifying diagnosis and a cooperative plan this is the cheapest route, and a legitimate compounded-medication provider will tell you so.

A compounded preparation is made by a licensed pharmacy for one named patient, against one prescription, from semaglutide base obtained from an FDA-registered supplier. It shares the active ingredient with the branded product. It does not share the approval, the pre-filled pen or the manufacturing-scale batch testing. What replaces those is state board of pharmacy oversight, USP sterile-compounding standards, and a pharmacy that is named on your label and answerable to you.

Compounded semaglutide is not FDA approved, and no compounded drug is. A provider that describes its compounded product as "FDA approved" is either confused about its own supply chain or hoping you are.

The third product is sold as "semaglutide" by chemical suppliers under a label stating it is not for human consumption. There is no prescription, no pharmacy, no physician and no accountability. The FDA's specific concern with this category is that much of it is a salt form: "These salt forms, including semaglutide sodium and semaglutide acetate, are different active ingredients," and the agency has said it is not aware of any basis for compounding with them.

This is not a technicality. The approved drug is semaglutide base; a sodium or acetate salt has a different molecular weight, different solubility and no clinical testing in people. Nobody buying from that channel can know what dose they are taking, or whether the powder is sterile.

Telehealth prescribing is state-by-state. The physician who reviews your intake must hold a license in the state where you are when you are treated, and a legitimate provider can tell you who reviewed your case. A service that cannot name a prescriber, or that says a "medical team" approved you, has not necessarily had a physician look at your file.

You should know which pharmacy compounded your medication before it arrives, and it should be on the label when it does. A state-licensed pharmacy has a license number you can check with that state's board of pharmacy. The pharmacy's FDA registration is a separate, checkable fact. A provider that will not tell you where the medication comes from is asking you to trust a supply chain it will not describe.

A compounding pharmacy tests its preparations for potency and sterility, and a provider that takes quality seriously will show you what that testing looks like. Pepti publishes its pharmacy testing at lab results, and the overall quality process at quality. What to look for on a certificate of analysis: the preparation name and strength, the lot, the assay result against the labeled strength, and sterility and endotoxin results. A vague "third-party tested" claim with nothing attached is not the same thing.

A legitimate compounded medication arrives labeled with your name, the drug and strength, the directions, the pharmacy's name and contact details, the prescriber, the date and a beyond-use date. A vial with a brand-style sticker and no patient name, or a bag of lyophilized powder with a separate vial of bacteriostatic water, did not come from a pharmacy filling a prescription for you.

The FDA has warned that counterfeit versions of the branded pens are in circulation, and that counterfeit drugs "could contain the wrong ingredients, contain too little, too much or no active ingredient at all or other harmful ingredients." A branded pen at a fraction of the pharmacy price from a site that is not a licensed pharmacy is the highest-risk purchase in this category, because it is designed to be indistinguishable from the real thing.

The FDA's concerns page describes adverse event reports involving "patients measuring and self-administering incorrect doses" and "health care professionals miscalculating doses" with compounded products, often because the concentration on the vial differed from what the patient or provider assumed. This is why the directions on a legitimate label are written in milliliters and syringe units for the specific strength in your hand, and why a provider that ships one concentration and tells you to "adjust" it for each rung has removed the safeguard.

The FDA's own list of warning signs for online GLP-1 sellers includes companies offering "deep discounts or prices that seem too good to be true" and those not requiring "a screening and prescription by a licensed doctor." Compounded semaglutide has a real cost floor: the base material, sterile compounding, cold shipping and a physician's time. A price far below that floor means one of those things is missing. Referral codes, countdown timers and "only three spots left" are retail mechanics, not medical ones.

The pharmacy's cost scales with the amount of semaglutide in the vial, so a 2 mg weekly rung costs more to compound than a 0.25 mg starting rung. A provider that charges one flat price for every rung is either overcharging you at the bottom or subsidizing the top. Per-rung pricing is the honest version. The current figure for each rung is on the semaglutide cost page; tirzepatide is priced the same way.

Medication, the physician review, refill management and refrigerated shipping. Injection supplies should be included or clearly listed. There should be no separate membership fee sitting underneath the medication price. If any of those appear as line items at checkout that were not in the headline, the headline was marketing. A research-chemical vial is cheapest because it comes with no physician, no pharmacy, no sterility testing and no one to call; the saving is the cost of everything that was removed.

If your plan covers a branded semaglutide product for your diagnosis, your copay may well be lower than any compounded price. Plans generally require a qualifying BMI or diagnosis and often prior authorization. Ask before paying cash. The mechanics are in does insurance cover peptide therapy.

Compounded semaglutide reached the mainstream during the FDA drug-shortage period, when compounders were permitted to make copies of a drug in shortage. The FDA determined that the shortage of semaglutide injection products was resolved on 21 February 2025. Enforcement discretion for 503A pharmacies then ended on 22 April 2025, and for 503B outsourcing facilities on 22 May 2025, following a court decision in April 2025. For tirzepatide, the shortage was declared resolved on 19 December 2024, with 503A discretion ending 18 February 2025 and 503B on 19 March 2025.

Outside a shortage, the law restricts compounding a preparation that is essentially a copy of a commercially available drug. The FDA's working definition is a preparation with the same active ingredient in a comparable strength by the same route, unless the prescriber documents a significant difference for that individual patient. That is why a legitimate compounded prescription is individualized to you by a physician rather than a generic order, and why the intake and the physician's notes are not formalities.

On 30 April 2026 the FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list. If finalized, outsourcing facilities would not be permitted to compound these drugs from bulk substances except during a declared shortage, on the basis that the agency found insufficient evidence of a clinical need. The proposal was open for public comment until 29 June 2026 and, as of this page's verification, is a proposal rather than a final action. The press release addresses 503B outsourcing facilities, which compound in bulk without patient-specific prescriptions; it does not address 503A pharmacies compounding to an individual prescription, which is how a prescription written for you is filled.

None of the 2025 and 2026 actions change the basics: semaglutide is a lawful, FDA-approved active ingredient, a physician can prescribe a compounded preparation of it to an individual patient, and a state-licensed pharmacy can compound and dispense it to that prescription. What they narrow is copying the branded product at scale. Compounded semaglutide remains not FDA approved as a finished product, which is true of every compounded medication.

STEP 1 (New England Journal of Medicine, 2021) randomized 1,961 adults with overweight or obesity and no diabetes to weekly semaglutide 2.4 mg or placebo alongside lifestyle intervention for 68 weeks, and reported a mean weight change of about 14.9% with semaglutide against about 2.4% with placebo. STEP 2 (The Lancet, 2021) ran the same design in adults with type 2 diabetes and reported smaller but still substantial differences from placebo. STEP 3 (JAMA, 2021) added semaglutide to intensive behavioral therapy and reported greater weight loss than behavioral therapy alone. STEP 5 (Nature Medicine, 2022) reported weight loss maintained over two years with continued treatment. STEP 8 (JAMA, 2022) reported greater weight loss with weekly semaglutide than with daily liraglutide.

STEP 4 (JAMA, 2021) is the study to know if you are deciding whether to start. After a 20-week run-in on semaglutide, participants were randomized to continue or to switch to placebo. Those who switched regained much of the lost weight over the next 48 weeks, while those who continued kept losing. That finding is the trial-level reason an honest provider talks about long-term treatment, and about protein and training, from the first conversation.

SELECT (New England Journal of Medicine, 2023) enrolled over 17,000 adults with established cardiovascular disease and overweight or obesity but without diabetes, and reported a lower rate of major adverse cardiovascular events with semaglutide than with placebo. SUSTAIN-6 (New England Journal of Medicine, 2016) had earlier reported a cardiovascular outcomes benefit in adults with type 2 diabetes. ESSENCE (New England Journal of Medicine, 2025) reported improvement in liver histology in adults with metabolic dysfunction-associated steatohepatitis. These are outcomes trials in specific populations on the branded products; they are not evidence about compounded preparations and they do not apply to everyone considering semaglutide. The point for a buyer is the breadth of the evidence base, which is a different situation from almost every other peptide on this site.

SURMOUNT-5 (New England Journal of Medicine, 2025) compared tirzepatide directly with semaglutide in adults with obesity and reported greater weight loss with tirzepatide over 72 weeks. Tirzepatide acts at both GIP and GLP-1 receptors; semaglutide acts at GLP-1 alone. That trial does not make tirzepatide the right choice for every patient: cost, side-effect experience and history all bear on it, and the decision is the prescriber's. The comparison is in semaglutide vs tirzepatide.

• It does not establish how any individual will respond. Trial means hide wide variation, and a real fraction of participants lost little.
• It does not establish results for compounded preparations, which have not been the subject of randomized trials.
• It does not establish that the medication works without the dietary and activity changes that accompanied it in every trial.
• It does not establish that weight stays off after stopping; STEP 4 suggests the opposite for most people.